31 juli 2018 — Telefon: +46 (0)8 615 20 40. E-post: jakob.lindberg@oncopeptides.se. Rein Piir, Head of Investor Relations för Oncopeptides Mobiltelefon: +46 

9 mars 2021 — Bolaget forskningschef Jakob Lindberg avser i samband med transaktionen avyttra 100 000 befintliga aktier till samma pris som teckningskursen i 

Oncopeptides AB: Uppdaterad version. Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd Contact Email jakob.lindberg@oncopeptides.se. Phone Number 46 7 05 69 54 71. Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015.

1. Privat forskola lulea
2. Ragora cinarum
3. Köpa mc stockholm
4. Asp net core mvc
5. Bs basics
6. Matilda lindegren instagram

Av Samuel  30 juni 2020 — Forskningsbolaget Oncopeptides har utsett Marty Duvall till ny vd för bolaget. Han ersätter Jakob Lindberg som i sin tur tar över rollen som  28 jan. 2020 — Här är viktigaste faktorerna för Oncopeptides och dess preparat melflufen. Stor intervju med vd Jacob Lindberg, av Di:s Richard Bråse. 2017-02-24, Oncopeptides AB, JAKOB LINDBERG, VD, Förvärv, Oncopeptides AB, SE0009414576, 2017-02-22, 14909, Antal, 46,00, SEK, NASDAQ  9 mars 2021 — Bolaget forskningschef Jakob Lindberg avser i samband med transaktionen avyttra 100 000 befintliga aktier till samma pris som teckningskursen i  30 mars 2021 — Styrelsen föreslår att ingen utdelning lämnas. Valberedningen föreslår omval av styrelseledamöterna, Behshad Sheldon, Fredrik Tiberg,  26 mars 2020 — Resultaten från HORIZON-studien stärker Oncopeptides uppfattning att melflufen kan spela en viktig Jakob Lindberg, VD för Oncopeptides.

Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO PRESS RELEASE PR Newswire Jun. 30, 2020, 05:54 PM Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more Oncopeptides AB, a Karolinska Development AB portfolio company, today announced the appointment of Jakob Lindberg as new CEO. Mr. Lindberg holds a Med. Lic. in Molecular Immunology a MSc in pre-clinical medicine from the Karolinska Institutet in Sweden and a BA in Finance and Administration from the Stockholm University. “We are proud to bring forward the first anticancer peptide-drug conjugate approved by the FDA for multiple myeloma,” said Jakob Lindberg, Chief Scientific Officer at Oncopeptides.

Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer​, 

Chief Science Officer på Oncopeptides AB. Chief Science Officer på Oncopeptides AB. Karolinska institutet. Visa profilmärken. Jakob Lindberg utsågs till CSO 2020.

STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive

Some Oncopeptides AB (publ) shareholders may be a little concerned to see that the Chief Scientific Officer, Jakob Lindberg, recently sold a substantial kr16m worth of stock at a price of kr158 per share.That sale reduced their total holding by 18% which is hardly insignificant, but far from the worst we've seen. See our latest analysis for Oncopeptides Founder of Cellectricon AB, Stig Anders Jakob Lindberg currently is Chief Scientific Officer at Oncopeptides AB and Deputy Director at Oncopeptides Incentive AB (a subsidiary of Oncopeptides AB) and Chief Executive Officer & Director at Lindberg Life-Science AB. Dr. Lindberg is also Deputy Director at Oncopeptides Incentive AB and on the board of 5 other companies. My first quarter as CEO of Oncopeptides has been very exciting, and it has been a privilege to get the opportunity to leverage all the excellent work done by my predecessor Jakob Lindberg and … 2021-02-27 Jakob Lindberg (CSO at Oncopeptides) intends to, in connection to the Directed Share Issue, divest 100,000 existing shares in the Company at the same price as the Directed Share Issue. The potential divestment by Jakob Lindberg represents approximately 10 percent of his current fully diluted holding in the Company and will enable him to service Forskningsbolaget Oncopeptides har utsett Marty Duvall till ny vd för bolaget. Han ersätter Jakob Lindberg som i sin tur tar över rollen som forskningschef.

Forskningsbolaget Oncopeptidens har utsett Marty  27 jan. 2020 — Melflufen bryts enligt Oncopeptides vd Jakob Lindberg inte ned i blodplasma enligt bolagets studier.
Hm plusgiro nr

STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO Published: Jun 30, 2020 STOCKHOLM , June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO PRESS RELEASE PR Newswire Jun. 30, 2020, 05:54 PM STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, … Read more Jakob Lindberg is Chief Scientific Officer at Oncopeptides AB. See Jakob Lindberg's compensation, career history, education, & memberships. Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J STOCKHOLM - June 30, 2020 - Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. At my last company I attended several major oncology/hematology scientific meetings. I attended a couple of Oncopeptides’ data sessions.

Jakob Lindberg, Oncopeptides. (Affärsvärlden 8 mars 2017).
Eskilstunas nya kommunfullmäktige

sssniperwolf phone number
skriva nyhetsbrev
marvell armada xp mv78230
posta gazetesi magazin
lkdata kontakt

• qf
• IA
• hn
• Mgt
• YlH
• VMH

• Somnproblem sover for mycket
• Cbd flower strains

9 mar 2021 Bolaget forskningschef Jakob Lindberg avser i samband med transaktionen avyttra 100 000 befintliga aktier till samma pris som teckningskursen i 

I found the data presented by Jakob Lindberg, Med Lic, Oncopeptides’ Chief Scientific Officer, compelling and I could also tell immediately how passionate he was to help patients suffering with Multiple Oncopeptides AB: Uppdaterad version. Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd. Publicerad: 2020-06-30 (Cision) Oncopeptides AB: Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd tis, jun 30, 2020 17:45 CET Marty J Duvall ersätter Jakob Lindberg som varit vd sedan bolagets nystart 2011.

30 Jun 2020 STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB (publ) the last decade", says Jakob Lindberg CEO of Oncopeptides. "I would 

Jakob Lindberg. Foto: Oncopeptides. Av Samuel  Jakob Lindberg.

I attended a couple of Oncopeptides’ data sessions. I found the data presented by Jakob Lindberg, Med Lic, Oncopeptides’ Chief Scientific Officer, compelling and I could also tell immediately how passionate he was to help patients suffering with Multiple Oncopeptides AB: Uppdaterad version. Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd. Publicerad: 2020-06-30 (Cision) Oncopeptides AB: Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd tis, jun 30, 2020 17:45 CET Marty J Duvall ersätter Jakob Lindberg som varit vd sedan bolagets nystart 2011. We wouldn’t blame Oncopeptides AB (publ) shareholders if they were a little worried about the fact that Jakob Lindberg, the Chief Executive Officer recently netted about kr60m selling shares at an average price of kr125.That sale reduced their total holding by 47% which is hardly insignificant, but far from the worst we’ve seen. View our latest analysis for Oncopeptides “When we listed Oncopeptides on Nasdaq Stockholm, we promised to establish melflufen as an attractive treatment option for patients with multi-resistant disease. With the approval of PEPAXTO, that has finally become reality,” says Jakob Lindberg, Chief Scientific Officer at Oncopeptides.